Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Biochim Biophys Acta Mol Cell Res. 2018 Oct 13;1866(3):450–458. doi: 10.1016/j.bbamcr.2018.10.008

Figure 1. Cten is a CRM-1-dependent nucleocytoplasmic shuttling protein.

Figure 1.

(A) Lung cancer cells A549, colorectal cancer SW480 cells, and cervical cancer HeLa cells were untreated or treated with 20 ng/mL of LMB for 6h or 24h. Nuclear and cytoplasmic fractions were prepared as description in Materials and Methods. Equal amounts of nuclear and cytoplasmic fractions (10 μg) were analyzed by immunoblotting with anti-Cten, anti-lamin A/C, or anti-α-tubulin antibodies. Right: The proportions of nuclear and cytoplasmic Cten measured by immunoblotting after subcellular fractionation in cells treated with LMB for 0h or 6h. HeLa (B) or A549 (C) cells treated with or without 20 ng/mL LMB for 6h were then fixed, permeabilized, and stained for DNA using DAPI (blue), for F-actin using Alexa Fluor 594 Phalloidin (red), and for Cten using a rabbit anti-Cten antibody followed by Alexa-488-coupled anti-rabbit IgG (green). Images were obtained by confocal laser scanning microscopy. Scale bars, 50 μm.